SCHEMBL1170580

SCHEMBL1170580

CC(=O)N(CC(=O)O)C(=O)C(Nc1cccc(C(F)(F)F)c1)C(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.49
CTSB P07858 1/20 0.49
CTSK P43235 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 1/20 0.45
TP53 P04637 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
MMP2 P08253 1/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
MAPT P10636 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
GAA P10253 1/20 0.43
XBP1 P17861 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17848962 0.84 ALDH1A1 (0.41) CTSLCTSBCTSKSMN1; SMN2KDM4E
SCHEMBL11206190 0.79 NPSR1 (0.60) CTSLCTSBCTSKSMN1; SMN2KDM4E
SCHEMBL11206192 0.79 NPSR1 (0.60) CTSLCTSBCTSKSMN1; SMN2KDM4E
SCHEMBL3468963 0.77 CTSL (0.53) CTSLCTSBCTSKSMN1; SMN2KDM4E
SCHEMBL2473494 0.77 CTSL (0.53) CTSLCTSBCTSKSMN1; SMN2KDM4E
SCHEMBL17848980 0.77 ALDH1A1 (0.35) MAPTGAAALDH1A1
SCHEMBL17849026 0.76 MAPT (0.36) CTSLCTSBCTSKSMN1; SMN2CA12
SCHEMBL17848983 0.76 MEN1 (0.35) SMN1; SMN2KDM4EMEN1KMT2AMAPT
SCHEMBL17849020 0.75 KMT2A (0.38) SMN1; SMN2KDM4ECA12CA1MMP2
Methyl Alcohol SCHEMBL17848974 0.75 MEN1 (0.35) SMN1; SMN2KDM4EMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070202203-A1 ANTI-AGEING COMPOSITION L'OREAL (FR) 2007-08-30 US claimed
EP-1889642-B1 Cosmetic compositions combining a C-glycoside derivative and a N-acylaminoamide derivative OREAL (FR) 2019-05-08 EP disclosed
US-10173080-B2 Dehydroascorbic acid or monomeric, polymeric or isomeric derivative thereof and an amine for artificially coloring the skin L'OREAL (FR) 2019-01-08 US disclosed
EP-2753300-B1 COMBINATION OF CARRAGEENAN AND C-GLYCOSIDE AND USES THEREOF OREAL (FR) 2018-12-12 EP disclosed
US-9974984-B2 Combination of monosaccharides with antioxidants and use thereof L'OREAL (FR) 2018-05-22 US disclosed
EP-2204163-B1 Combination of monosaccharides and ascorbic acid and its use in cosmetic L'ORÉAL (FR) 2017-11-29 EP disclosed
EP-2223680-B1 Combination of monosaccharides and exfoliating agents and its cosmetic use L'ORÉAL (FR) 2017-10-18 EP disclosed
US-9643032-B2 Application of dehydroascorbic acid or derivatives/isomers thereof for artificially coloring the skin L'OREAL (FR) 2017-05-09 US disclosed
EP-1837013-B1 Composition comprising hydroxyapatite and a calcium salt for reinforcing the barrier function of the skin and/or semi-mucus membranes. L'ORÉAL (FR) 2017-04-19 EP disclosed
EP-2234674-B1 FLUID OIL-IN-WATER SUNSCREEN EMULSIONS CONTAINING A SELECTED GEMINI SURFACTANT AND A CROSSLINKED COPOLYMER OF METHACRYLIC ACID AND OF ETHYL ACRYLATE L'ORÉAL (FR) 2017-03-29 EP disclosed
EP-1897526-A1 Oil in water cosmetic emulsion L'Oréal (FR) 2008-03-12 EP disclosed
US-20080050333-A1 OIL-IN-WATER DISPERSION L'OREAL (FR) 2008-02-28 US disclosed
EP-1889642-A2 Cosmetic compositions combining a C-glycoside derivative and a N-acylaminoamide derivative L'OREAL (FR) 2008-02-20 EP disclosed
US-20080014230-A1 Cosmetic compositions combining a C-glycoside derivative and an N-acylamino amide derivative L'OREAL (FR) 2008-01-17 US disclosed
US-20080008673-A1 Compositions comprising at least one C-glycoside derivative L'OREAL S.A. (FR) 2008-01-10 US disclosed
WO-2008004164-A2 COSMETIC AND/OR DERMATOLOGICAL COMPOSITION COMBINING A C-GLYCOSIDE DERIVATIVE AND A DESQUAMATING AGENT L'OREAL (FR) 2008-01-10 WO disclosed
US-20070248633-A1 COMPOSITIONS CONTAINING A HYDROXYLATED DIPHENYLMETHANE COMPOUND, METHODS OF USE L'OREAL (FR) 2007-10-25 US disclosed
EP-1847247-A1 Compositions comprising a hydroxylated diphenyl-methane derivative L'OREAL (FR) 2007-10-24 EP disclosed
EP-1837013-A1 Composition comprising hydroxyapatite and a calcium salt for reinforcing the barrier function of the skin and/or semi-mucus membranes. L'OREAL (FR) 2007-09-26 EP disclosed
US-20070202203-A1 ANTI-AGEING COMPOSITION L'OREAL (FR) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080008673-A1 Compositions comprising at least one C-glycoside derivative DSG1, TYR, CUTA CTSL 1407/4885CTSB 723/4885CTSK 570/4885
US-20080050333-A1 OIL-IN-WATER DISPERSION DEGS1, ABHD6, MGLL CTSL 4869/4885CTSB 4878/4885CTSK 4875/4885
US-20070248633-A1 COMPOSITIONS CONTAINING A HYDROXYLATED DIPHENYLMETHANE COMPOUND, METHODS OF USE DPM1, CYP8B1, CUTA CTSL 4412/4885CTSB 3416/4885CTSK 3453/4885
US-20080014230-A1 Cosmetic compositions combining a C-glycoside derivative and an N-acylamino amide derivative AMDHD2, B3GNT2, CUTA CTSL 1886/4885CTSB 984/4885CTSK 1004/4885
US-10173080-B2 Dehydroascorbic acid or monomeric, polymeric or isomeric derivative thereof and an amine for artificially coloring the skin OXER1, AKR1B10, RBP1 CTSL 4100/4885CTSB 3021/4885CTSK 3525/4885
US-20070202203-A1 ANTI-AGEING COMPOSITION GLA, CUTA, CD44 CTSL 2864/4885CTSB 1507/4885CTSK 1560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.